###begin article-title 0
###xml 0 28 0 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Survival motor neuron gene 2</italic>
Survival motor neuron gene 2 silencing by DNA methylation correlates with spinal muscular atrophy disease severity and can be bypassed by histone deacetylase inhibition
###end article-title 0
###begin p 1
###xml 0 16 0 16 <!--CREATIVE COMMONS-->
CREATIVE COMMONSThis is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License () which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin p 2
###xml 103 131 103 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">survival motor neuron gene 1</italic>
###xml 133 137 133 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN1</italic>
###xml 205 209 205 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 361 365 361 365 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 420 424 420 424 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 544 548 544 548 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN1</italic>
###xml 601 605 601 605 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 687 691 687 691 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 864 868 864 868 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 929 933 929 933 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1118 1122 1118 1122 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1197 1201 1197 1201 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1427 1431 1427 1431 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1691 1695 1691 1695 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 561 569 <span type="species:ncbi:9606">patients</span>
###xml 621 629 <span type="species:ncbi:9606">patients</span>
Spinal muscular atrophy (SMA), a common neuromuscular disorder, is caused by homozygous absence of the survival motor neuron gene 1 (SMN1), while the disease severity is mainly influenced by the number of SMN2 gene copies. This correlation is not absolute, suggesting the existence of yet unknown factors modulating disease progression. We demonstrate that the SMN2 gene is subject to gene silencing by DNA methylation. SMN2 contains four CpG islands which present highly conserved methylation patterns and little interindividual variations in SMN1-deleted SMA patients. The comprehensive analysis of SMN2 methylation in patients suffering from severe versus mild SMA carrying identical SMN2 copy numbers revealed a correlation of CpG methylation at the positions -290 and -296 with the disease severity and the activity of the first transcriptional start site of SMN2 at position -296. These results provide first evidence that SMN2 alleles are functionally not equivalent due to differences in DNA methylation. We demonstrate that the methyl-CpG-binding protein 2, a transcriptional repressor, binds to the critical SMN2 promoter region in a methylation-dependent manner. However, inhibition of SMN2 gene silencing conferred by DNA methylation might represent a promising strategy for pharmacologic SMA therapy. We identified histone deacetylase (HDAC) inhibitors including vorinostat and romidepsin which are able to bypass SMN2 gene silencing by DNA methylation, while others such as valproic acid and phenylbutyrate do not, due to HDAC isoenzyme specificities. These findings indicate that DNA methylation is functionally important regarding SMA disease progression and pharmacological SMN2 gene activation which might have implications for future SMA therapy regimens.
###end p 2
###begin title 3
INTRODUCTION
###end title 3
###begin p 4
###xml 1151 1152 1151 1152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN357C1">1</xref>
###xml 321 329 <span type="species:ncbi:9606">Patients</span>
###xml 575 583 <span type="species:ncbi:9606">children</span>
###xml 838 846 <span type="species:ncbi:9606">patients</span>
###xml 1057 1065 <span type="species:ncbi:9606">patients</span>
Autosomal recessive proximal spinal muscular atrophy (SMA) is a severely progressing neuromuscular disorder and a major cause of inherited childhood lethality. SMA is characterized by the loss of lower motor neurons in the anterior horns of the spinal cord, causing symmetrical weakness and atrophy of voluntary muscles. Patients with SMA have been classified into four types depending on age of onset and progression of the disease: type I SMA is the most severe form with generalized muscle weakness and hypotonia and a disease onset within the first 6 months of life. The children are unable to sit or walk and usually die within the first 2 years of life. Type II SMA individuals are able to sit but unable to walk unaided. They usually present first symptoms after the first 6 months of life and survive beyond 2 years. Type III SMA patients are able to sit and walk, and the lifespan is not reduced. Disease onset before the age of 3 years is classified as type IIIa, whereas an age of onset beyond 3 years is classified as type IIIb SMA. Type IV SMA patients are mildly affected with an age of onset after the third decade of life (reviewed in 1).
###end p 4
###begin p 5
###xml 24 52 24 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">survival motor neuron gene 1</italic>
###xml 54 58 54 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN1</italic>
###xml 125 129 125 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN1</italic>
###xml 150 151 150 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN357C2">2</xref>
###xml 204 225 204 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">survival motor neuron</italic>
###xml 227 230 227 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN</italic>
###xml 232 236 232 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">gene</italic>
###xml 259 263 259 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN1</italic>
###xml 268 272 268 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 338 339 338 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN357C3">3</xref>
###xml 379 383 379 383 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN1</italic>
###xml 403 407 403 407 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 468 472 468 472 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 684 687 680 683 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN</italic>
###xml 701 702 697 698 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN357C4">4</xref>
###xml 747 751 743 747 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN1</italic>
###xml 798 802 794 798 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-SMN</italic>
###xml 829 833 825 829 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 893 897 885 889 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-SMN</italic>
###xml 916 917 904 905 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-</italic>
###xml 1024 1025 1012 1013 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN357C5">5</xref>
###xml 1026 1027 1014 1015 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN357C6">6</xref>
###xml 1103 1110 1091 1098 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1112 1113 1100 1101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN357C7">7</xref>
###xml 1206 1210 1194 1198 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1236 1237 1224 1225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN357C8">8</xref>
###xml 1238 1240 1226 1228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN357C11">11</xref>
###xml 1278 1282 1266 1270 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1378 1382 1366 1370 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1417 1421 1405 1409 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1451 1452 1439 1440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN357C9">9</xref>
###xml 1595 1599 1583 1587 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1657 1659 1645 1647 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN357C12">12</xref>
###xml 1662 1666 1650 1654 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1738 1742 1726 1730 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1779 1783 1767 1771 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1815 1819 1803 1807 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-SMN</italic>
###xml 101 109 <span type="species:ncbi:9606">patients</span>
###xml 198 203 <span type="species:ncbi:9606">human</span>
###xml 362 370 <span type="species:ncbi:9606">patients</span>
###xml 1259 1267 <span type="species:ncbi:9606">patients</span>
###xml 1311 1319 <span type="species:ncbi:9606">patients</span>
###xml 1349 1357 <span type="species:ncbi:9606">patients</span>
###xml 1399 1407 <span type="species:ncbi:9606">patients</span>
###xml 1643 1648 <span type="species:ncbi:10090">mouse</span>
The disease determining survival motor neuron gene 1 (SMN1) is homozygously absent in 96% of all SMA patients and intragenic SMN1 mutations are rare (2). Within the SMA region on chromosome 5q, the human survival motor neuron (SMN) gene exists in two copies, SMN1 and SMN2, which are ubiquitously expressed and encode identical proteins (3). Even though all SMA patients lacking SMN1 carry at least one SMN2 gene copy, the amount of functional SMN protein produced by SMN2 is not sufficient to prevent progressive alpha-motor neuron degeneration. This finding has been assigned to a single translationally silent 'C' to 'T' transition within exon 7, affecting the splicing of primary SMN transcripts (4). As a consequence, the disease determining SMN1 gene produces full-length transcripts only (FL-SMN), whereas the majority of SMN2 transcripts lack exon 7 due to alternative splicing (Delta7-SMN). Truncated Delta7-SMN proteins are reduced in their ability to self-oligomerize, which is essential for proper SMN function (5,6), and have been shown to ameliorate, but not to prevent, the SMA phenotype in vivo (7). However, several studies have revealed a strong inverse correlation between the number of SMN2 copies and SMA severity (8-11). Most type I SMA patients carry two SMN2 copies, whereas type II SMA patients carry three and type III SMA patients carry three or four SMN2 copies. Rarely, patients with two SMN2 copies show mild phenotypes (9), suggesting the influence of yet unidentified modifying factors modulating disease progression. Due to the disease modifying property of the SMN2 gene which has been verified in transgenic mouse models (12), SMN2 represents the major therapeutic target. Consequently, transcriptional SMN2 activation and/or modulation of the SMN2 splicing pattern to increase FL-SMN levels may be an effective strategy for SMA treatment.
###end p 5
###begin p 6
###xml 90 94 90 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 125 133 125 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 192 196 192 196 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 322 324 322 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN357C13">13</xref>
###xml 325 327 325 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN357C17">17</xref>
###xml 350 352 350 352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN357C15">15</xref>
###xml 353 355 353 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN357C18">18</xref>
###xml 420 422 420 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN357C15">15</xref>
###xml 423 425 423 425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN357C19">19</xref>
###xml 426 428 426 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN357C20">20</xref>
###xml 612 617 612 617 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 620 622 620 622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN357C17">17</xref>
###xml 688 692 688 692 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 774 779 774 779 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 782 784 782 784 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN357C21">21</xref>
###xml 1138 1140 1138 1140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN357C22">22</xref>
###xml 1141 1143 1141 1143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN357C23">23</xref>
###xml 1153 1155 1153 1155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN357C24">24</xref>
###xml 1156 1158 1156 1158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN357C25">25</xref>
###xml 1178 1185 1178 1185 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FL-SMN2</italic>
###xml 511 526 <span type="species:ncbi:10090">transgenic mice</span>
###xml 593 598 <span type="species:ncbi:10090">mouse</span>
###xml 749 753 <span type="species:ncbi:10090">mice</span>
###xml 947 951 <span type="species:ncbi:10090">mice</span>
###xml 1112 1120 <span type="species:ncbi:9606">patients</span>
###xml 1212 1220 <span type="species:ncbi:9606">patients</span>
Numerous small-molecule histone deacetylase (HDAC) inhibitors have been shown to increase SMN2-derived FL-SMN protein levels in vitro by transcriptional activation and/or by modulation of the SMN2 splicing pattern. These compounds include the fatty acids sodium butyrate (SB), phenylbutyrate (PB) and valproic acid (VPA) (13-17); the benzamide M344 (15,18) as well as the hydroxamic acids SAHA and trichostatin A (TSA) (15,19,20). The potential applicability of HDAC inhibitors for SMA therapy was confirmed in transgenic mice which mimic SMA-like features. By employing a knockout transgenic mouse model, Chang et al. (17) demonstrated that oral application of SB increased lifespan and SMN2-derived SMN protein levels in motor neurons of affected mice. Concordantly, Tsai et al. (21) demonstrated that oral application of VPA attenuates motor neuron death, increases spinal SMN protein levels and partially normalizes motor function in SMA-like mice. Clinical phase II trials have been initiated to evaluate the efficacy of the FDA-approved drugs PB and VPA for SMA therapy. Pilot trials with small numbers of patients treated with PB (22,23) or VPA (24,25) revealed elevated FL-SMN2 transcript levels in some patients and increased quantitative muscle strength and subjective muscle function, which might further emphasize the potential use of HDAC inhibitors for SMA treatment.
###end p 6
###begin p 7
###xml 152 156 152 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 457 459 457 459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN357C26">26</xref>
###xml 460 462 460 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN357C27">27</xref>
###xml 537 541 537 541 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 729 731 729 731 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN357C28">28</xref>
###xml 774 778 774 778 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 884 888 884 888 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
However, the efficacies of PB and VPA for SMA therapy await clinical confirmation and the mechanism(s) by which HDAC inhibitors elevate transcriptional SMN2 gene activity remain elusive. In general, HDAC inhibition promotes a more relaxed chromatin structure, allowing transcriptional activation. Given the fact that the fundamental mechanisms of epigenetic gene regulation, histone modification and DNA methylation have shown to be intimately interlinked (26,27), we hypothesized that DNA methylation plays a pivotal role in epigenetic SMN2 gene regulation and SMA pathogenesis. DNA methylation has been shown to be the most stable type of epigenetic modification modulating the transcriptional plasticity of mammalian genomes (28). However, the role of DNA methylation in SMN2 gene regulation has not been addressed so far. In this study, we demonstrate for the first time that the SMN2 gene is subject to gene silencing by DNA methylation, which might have major implications for SMA disease progression and upcoming pharmacological interventions for epigenetic SMA therapy.
###end p 7
###begin title 8
RESULTS
###end title 8
###begin title 9
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
SMN2 gene activity is reduced by DNA methylation
###end title 9
###begin p 10
###xml 70 74 70 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 157 161 157 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN1</italic>
###xml 261 265 261 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 409 414 409 414 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2-</italic>
###xml 520 521 520 521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN357F1">1</xref>
###xml 547 551 547 551 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 728 732 728 732 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 763 767 763 767 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 786 788 786 788 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN357C14">14</xref>
###xml 789 791 789 791 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN357C15">15</xref>
###xml 792 794 792 794 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN357C18">18</xref>
###xml 942 946 942 946 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 971 972 971 972 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN357F1">1</xref>
###xml 1082 1086 1082 1086 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1167 1168 1167 1168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN357F1">1</xref>
###xml 237 245 <span type="species:ncbi:9606">patients</span>
We raised the question whether the major target gene for SMA therapy, SMN2, is subject to gene silencing mediated by DNA methylation. To address this issue, SMN1-deleted fibroblast cell lines (ML5, ML16) derived from two independent SMA patients carrying three SMN2 copies were treated with various doses of 5-aza-2'-deoxycytidine (Aza), a well-established DNA-demethylating compound. Aza treatment increased SMN2-derived transcript and protein levels in a dose-dependent fashion in both SMA fibroblast cell lines (Fig. 1A and B), indicating that SMN2 gene activity is inversely correlated with DNA methylation. Using both cell lines, we previously have shown that HDAC inhibitors augment SMN2 protein levels by transcriptional SMN2 gene activation and increased SMN2 exon 7 inclusion (14,15,18). Concordantly, treatment of SMA fibroblasts (ML16) with effective doses of the experimental pan-HDAC inhibitor M344 significantly increased total SMN2 transcript levels (Fig. 1C). However, even though interference with either DNA methylation or HDAC activity was sufficient to increase SMN2 gene expression, there is no additive or synergistic effect when combined (Fig. 1C).
###end p 10
###begin p 11
###xml 16 44 16 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">survival motor neuron gene 2</italic>
###xml 46 50 46 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 125 129 125 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN1</italic>
###xml 197 201 197 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 214 215 214 215 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 242 243 242 243 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 426 430 424 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 529 530 522 523 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 553 557 546 550 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 690 691 682 683 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 711 715 703 707 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 817 821 808 812 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 919 920 906 907 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 951 955 938 942 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1029 1030 1012 1013 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 1077 1078 1060 1061 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1087 1088 1070 1071 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 1162 1163 1141 1142 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 1256 1257 1229 1230 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 1263 1264 1236 1237 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1273 1274 1246 1247 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
Transcriptional survival motor neuron gene 2 (SMN2) activation by the DNA-demethylating drug 5-aza-2'-deoxycytidine (Aza) in SMN1-deleted SMA (spinal muscular atrophy) fibroblasts. Bar graphs show SMN2 transcript (A) and SMN2 protein levels (B) in ML5 and ML16 fibroblast cell lines treated with various doses of Aza for 72 h (mean +/- SEM). Expression levels in solvent- and time-matched controls were set to 100%. Increased SMN2 transcript levels (normalized to ss-actin) were observed following Aza treatment (1, 10, 100 microm) and a dose-dependent SMN2 gene activation was confirmed on protein level (normalized to ss-tubulin). A representative western blot analysis (ML16) is shown. (C) Quantification of SMN2 transcript levels (normalized to ss-actin) in ML16 cells after treatment with different doses of the SMN2-activating HDAC (histone deacetylase) inhibitor M344 either alone or in combination with 10 microm Aza for 48 h. Transcriptional SMN2 gene activation either by M344 alone or in combination with Aza (10 microm) reached levels of significance in all cases (P < 0.05, t-test). A >5-fold induction was observed following treatment with 10 microm M344 (546 +/- 53%), while no additive effects were observed after co-treatment with 10 microm Aza (P > 0.05, t-test).
###end p 11
###begin title 12
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
SMN2 is a methylated gene containing four CpG islands
###end title 12
###begin p 13
###xml 63 67 63 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 202 206 202 206 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 286 306 286 306 <uri xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:type="simple" xlink:href="www.EBI.ac.uk/emboss">www.EBI.ac.uk/emboss</uri>
###xml 446 450 434 438 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 468 469 456 457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN357F2">2</xref>
###xml 527 531 515 519 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 527 531 515 519 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 605 609 593 597 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 605 609 593 597 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 640 644 628 632 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 640 644 628 632 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 675 679 663 667 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 675 679 663 667 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 713 717 701 705 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 713 717 701 705 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 827 831 815 819 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 827 831 815 819 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 913 915 901 903 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN357C29">29</xref>
###xml 1266 1270 1254 1258 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN1</italic>
###xml 1364 1368 1352 1356 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1430 1431 1418 1419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN357F2">2</xref>
###xml 1435 1439 1423 1427 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1435 1439 1423 1427 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 1449 1453 1437 1441 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1449 1453 1437 1441 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 1534 1538 1522 1526 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1534 1538 1522 1526 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 1642 1646 1630 1634 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1642 1646 1630 1634 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 1857 1861 1845 1849 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1857 1861 1845 1849 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 1871 1875 1859 1863 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1871 1875 1859 1863 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 1916 1920 1904 1908 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1916 1920 1904 1908 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 1974 1978 1962 1966 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1974 1978 1962 1966 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 2029 2030 2017 2018 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN357F2">2</xref>
To identify putative CpG islands (CGIs) involved in epigenetic SMN2 gene regulation by DNA methylation, we analysed the genomic region 3000 nucleotides (nt) upstream and downstream of the translational SMN2 start site (defined as nt position +1). By employing the CGI finder algorithm (www.EBI.ac.uk/emboss) we identified four putative CGIs that localize within a approximately2 kb genomic region (nt -896 to +1146) surrounding the translational SMN2 start site (Fig. 2A). These four putative CGIs, subsequently referred to as SMN2CGIs, contain a total of 85 CpG dinucleotides, 14 of which are located in SMN2CGI 1 (nt -896 to -645), 12 in SMN2CGI 2 (nt -469 to -247), 38 in SMN2CGI 3 (nt -151 to +295) and 21 in SMN2CGI 4 (nt +844 to +1146). To quantify DNA methylation levels of each CpG dinucleotide located within the four SMN2CGIs, we performed bisulphite genomic sequencing using pyrosequencing technology (29). The method is based on the selective deamination of unmethylated cytosine to uracil by treatment with bisulphite, while 5-methylcytosine remains unchanged. Pyrosequencing of subsequently generated PCR (polymerase chain reaction) products allows for both the detection and the quantification of cytosine methylation. Using genomic DNA isolated from SMN1-deleted SMA fibroblasts (ML5, ML16), bisulphite genomic sequencing revealed almost identical SMN2 methylation patterns in both SMA fibroblast cell lines (Fig. 2B). SMN2CGI 1 and SMN2CGI 4 were hypermethylated in both cell lines with mean methylation levels >70%. SMN2CGI 3 was hypomethylated (mean methylation levels <10%) with a single outlier at nt position +89, while SMN2CGI 2 displayed intermediate mean methylation levels. Using bisulphite-treated DNA derived from ML5 and ML16 SMA fibroblasts as templates, cloning and sequencing of PCR products revealed similar results. Again, SMN2CGI 1 and SMN2CGI 4 were almost completely methylated, SMN2CGI 3 was nearly unmethylated (data not shown), while SMN2CGI 2 showed intermediate methylation levels (Fig. 2C).
###end p 13
###begin p 14
###xml 0 28 0 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Survival motor neuron gene 2</italic>
###xml 30 34 30 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 197 201 197 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 299 319 299 319 <uri xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:type="simple" xlink:href="www.EBI.ac.uk/emboss">www.EBI.ac.uk/emboss</uri>
###xml 405 409 405 409 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 405 409 405 409 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 433 437 433 437 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 433 437 433 437 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 461 465 461 465 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 461 465 461 465 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 489 493 489 493 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 489 493 489 493 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 519 523 519 523 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 519 523 519 523 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 598 602 598 602 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 701 705 701 705 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 701 705 701 705 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 712 714 712 714 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN357C30">30</xref>
###xml 715 717 715 717 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN357C31">31</xref>
###xml 721 722 721 722 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 780 784 780 784 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 780 784 780 784 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 905 907 905 907 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN357C30">30</xref>
###xml 908 910 908 910 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN357C31">31</xref>
###xml 914 915 914 915 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 1006 1010 1006 1010 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1006 1010 1006 1010 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 1110 1114 1110 1114 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1110 1114 1110 1114 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 1172 1176 1172 1176 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1172 1176 1172 1176 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 1190 1194 1190 1194 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1190 1194 1190 1194 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 1208 1212 1208 1212 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1208 1212 1208 1212 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 1225 1229 1225 1229 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1225 1229 1225 1229 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 1249 1253 1249 1253 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1249 1253 1249 1253 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 1267 1271 1267 1271 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1267 1271 1267 1271 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 1285 1289 1285 1289 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1285 1289 1285 1289 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 1302 1306 1302 1306 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1302 1306 1302 1306 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 1321 1322 1321 1322 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 1348 1352 1348 1352 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1348 1352 1348 1352 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 1359 1363 1359 1363 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1359 1363 1359 1363 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 1373 1377 1373 1377 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1373 1377 1373 1377 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 1495 1499 1495 1499 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1495 1499 1495 1499 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 1606 1610 1606 1610 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1606 1610 1606 1610 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
Survival motor neuron gene 2 (SMN2) is a methylated gene containing four CpG islands (CGIs). Putative CGIs within the genomic region 3000 nucleotides (nt) upstream and downstream the translational SMN2 start site (NCBI36: 5:70254287:70248287) were identified using the CGI finder and plotting tool (www.EBI.ac.uk/emboss). This algorithm identified four putative CGIs within the respective genomic region (SMN2CGI 1: nt -896 to -645, SMN2CGI 2: nt -469 to -247, SMN2CGI 3: nt -151 to +295, SMN2CGI 4: nt +844 to +1146). SMN2CGI 2 contains the first out of three transcriptional start sites (TSS) of SMN2 at nt -296, while the second TSS at nt position -242 is located close to the downstream border of SMN2CGI 2 (30,31). (A) Schematically illustrates the localizations of all four SMN2CGIs within the analysed genomic region. The localizations of the TSS at nt positions -296, -242 and -163 are indicated (30,31). (B) Frequency plots illustrating the methylation levels of each CpG dinucleotide within each SMN2CGI in the respective SMA(Spinal muscular atrophy)-fibroblasts. The mean methylation levels of each SMN2CGI, indicated by a horizontal line, are as follows: ML5: SMN2CGI 1: 87.1%, SMN2CGI 2: 36.6%, SMN2CGI 3: 6.9%, SMN2CGI 4: 75.9%; ML16: SMN2CGI 1: 87.7%, SMN2CGI 2: 37.7%, SMN2CGI 3: 6.2%, SMN2CGI 4: 73.4%. (C) Methylation analysis of SMN2CGI 1, SMN2CGI 2 and SMN2CGI 4 in ML5 and ML16 fibroblasts cell lines by bisulphite treatment, followed by PCR amplification of the respective SMN2CGI, cloning of PCR products, and sequencing. The methylation patterns of nine independent clones for each SMN2CGI and each cell line are shown. Empty circles represent unmethylated CpGs, whereas full circles correspond to their methylated status.
###end p 14
###begin title 15
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
SMN2 gene methylation patterns are highly conserved and correlate with SMA severity
###end title 15
###begin p 16
###xml 21 25 21 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN1</italic>
###xml 60 64 60 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 185 186 173 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN357C9">9</xref>
###xml 292 296 280 284 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 419 423 407 411 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 419 423 407 411 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 491 495 479 483 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN1</italic>
###xml 537 541 525 529 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 617 621 605 609 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 694 695 682 683 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN357F3">3</xref>
###xml 715 719 703 707 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 796 800 784 788 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 796 800 784 788 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 810 814 798 802 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 810 814 798 802 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 852 856 840 844 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 852 856 840 844 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 922 926 910 914 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 922 926 910 914 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 1153 1154 1141 1142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN357F3">3</xref>
###xml 1244 1248 1232 1236 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN1</italic>
###xml 1292 1296 1280 1284 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1387 1388 1375 1376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN357F3">3</xref>
###xml 1580 1584 1568 1572 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1580 1584 1568 1572 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 1607 1611 1595 1599 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1607 1611 1595 1599 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 1638 1642 1626 1630 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1638 1642 1626 1630 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 1677 1678 1665 1666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN357F3">3</xref>
###xml 1977 1981 1965 1969 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1977 1981 1965 1969 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 2044 2045 2028 2029 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 2058 2059 2042 2043 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 2152 2156 2136 2140 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 2163 2164 2147 2148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN357F2">2</xref>
###xml 2168 2170 2152 2154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN357C30">30</xref>
###xml 2171 2173 2155 2157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN357C31">31</xref>
###xml 2447 2449 2431 2433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN357C28">28</xref>
###xml 38 46 <span type="species:ncbi:9606">patients</span>
###xml 117 125 <span type="species:ncbi:9606">patients</span>
###xml 515 523 <span type="species:ncbi:9606">patients</span>
###xml 1138 1146 <span type="species:ncbi:9606">patients</span>
###xml 1270 1278 <span type="species:ncbi:9606">patients</span>
###xml 1832 1840 <span type="species:ncbi:9606">patients</span>
###xml 2228 2236 <span type="species:ncbi:9606">patients</span>
The vast majority of SMN1-deleted SMA patients carrying two SMN2 copies suffer from type I or II SMA, while only few patients (approximately2%) develop a mild (type III SMA) phenotype (9), suggesting the existence of a yet unknown factor counteracting disease progression. To address whether SMN2 gene methylation correlates with the disease severity, we analysed methylation levels of each CpG dinucleotide within the SMN2CGIs using DNA isolated from blood samples taken from 10 unrelated, SMN1-deleted type I SMA patients carrying two SMN2 copies (six females, four males). Bisulphite genomic sequencing identified SMN2 methylation patterns similar to those observed in SMA fibroblasts (Fig. 3A), suggesting that SMN2 gene methylation patterns do not essentially differ between tissues. Again, SMN2CGI 1 and SMN2CGI 4 appeared to be hypermethylated, SMN2CGI 3 hypomethylated with a single outlier at position +89, while SMN2CGI 2 displayed intermediate mean methylation levels. An unexpected observation was that methylation levels of each single CpG dinucleotide showed only little interindividual variations between the 10 type I SMA patients (Fig. 3A). The subsequent analysis of DNA isolated from blood samples taken from seven available SMN1-deleted type III SMA patients carrying two SMN2 copies (four females, three males) again revealed little interindividual variations (Fig. 3B). However, the comparison of methylation levels of each CpG dinucleotide identified significant correlations between CpG methylation levels and the disease severity at seven CpGs located in SMN2CGI 1 (nt -871, -695), SMN2CGI 2 (nt -296, -290), and SMN2CGI 4 (nt +855, +988, +1103) (Fig. 3C). At six sites (nt -871, -695, -296, -290, +855, +1103), significantly lower methylation frequencies were observed in type III compared with type I SMA patients. A striking finding at this point was that the most pronounced differences in CpG methylation levels were observed at nt position -296 (SMN2CGI 2; type I SMA: 94.1 +/- 6.3%; type III SMA: 66.7 +/- 8.0%, P = 0.000084, t-test), which exactly represents the first out of three transcriptional start sites (TSS) of SMN2 (Fig. 2A) (30,31). The correlation of CpG methylation levels of all 17 patients with their gender (10 females, seven males) did not reveal any significant results (data not shown), which is in line with a previous comprehensive study showing that DNA methylation is not affected by gender (28).
###end p 16
###begin p 17
###xml 0 28 0 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Survival motor neuron gene 2</italic>
###xml 30 34 30 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 248 252 246 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 248 252 246 250 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 303 307 301 305 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN1</italic>
###xml 342 346 340 344 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 355 356 353 354 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 358 359 356 357 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 370 371 368 369 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 405 406 403 404 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 434 438 432 436 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 598 602 596 600 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 598 602 596 600 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 671 675 669 673 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 671 675 669 673 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 689 693 687 691 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 689 693 687 691 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 707 711 705 709 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 707 711 705 709 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 724 728 722 726 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 724 728 722 726 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 757 761 755 759 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 757 761 755 759 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 775 779 773 777 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 775 779 773 777 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 793 797 791 795 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 793 797 791 795 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 810 814 808 812 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 810 814 808 812 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 828 832 826 830 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 995 996 993 994 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 1362 1363 1360 1361 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1374 1375 1372 1373 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1387 1388 1385 1386 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1398 1399 1396 1397 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 138 146 <span type="species:ncbi:9606">patients</span>
###xml 320 328 <span type="species:ncbi:9606">patients</span>
###xml 395 403 <span type="species:ncbi:9606">patients</span>
###xml 985 993 <span type="species:ncbi:9606">patients</span>
###xml 1169 1177 <span type="species:ncbi:9606">patients</span>
Survival motor neuron gene 2 (SMN2) methylation patterns are highly conserved in blood samples derived from spinal muscular atrophy (SMA) patients. Bar charts show the mean methylation levels (+/-SEM) of each CpG dinucleotide within the respective SMN2CGIs in DNA isolated from blood samples drawn from SMN1-deleted SMA patients carrying two SMN2 copies (A, B). Type I (n = 10) and type III SMA patients (n = 7) show highly conserved SMN2 methylation patterns as can be deduced from the comparatively low SEM for the methylation levels of each CpG dinucleotide. The mean methylation levels of each SMN2CGI (see frequency plot) in both groups are as follows: type I SMA - SMN2CGI 1: 89.1%, SMN2CGI 2: 58.0%, SMN2CGI 3: 4.6%, SMN2CGI 4: 79.9%; type III SMA - SMN2CGI 1: 85.5%, SMN2CGI 2: 52.6%, SMN2CGI 3: 4.8%, SMN2CGI 4: 78.1%. SMN2 methylation correlates with the disease severity. Bar chart shows differences in DNA methylation at each CpG dinucleotide in type I versus type III SMA patients (C). Seven CpG dinucleotides (nt -871, -695, -296, -290, +855, +988, +1103) were identified whose methylation frequencies differ by at least 10% in type I versus type III SMA patients. Correlations between CpG methylation frequencies and disease severity reached levels of significance in all seven cases. Three levels of statistical significance were discriminated: *P < 0.05, **P < 0.01, ***P < 0.001 (t-test).
###end p 17
###begin title 18
###xml 54 58 54 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
Reduced methylation at positions -296 and -290 of the SMN2 gene is associated with mild SMA in SMA fibroblasts
###end title 18
###begin p 19
###xml 34 38 34 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 141 145 141 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN1</italic>
###xml 186 190 186 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 285 289 285 289 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 285 289 285 289 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 458 459 458 459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN357F4">4</xref>
###xml 662 663 662 663 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN357F3">3</xref>
###xml 780 784 780 784 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 899 903 899 903 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 970 990 970 990 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">long transcript SMN2</italic>
###xml 992 999 992 999 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LT-SMN2</italic>
###xml 1065 1072 1065 1072 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LT-SMN2</italic>
###xml 1142 1149 1142 1149 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LT-SMN2</italic>
###xml 1248 1249 1248 1249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN357F4">4</xref>
###xml 1397 1404 1397 1404 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LT-SMN2</italic>
###xml 1442 1446 1442 1446 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 158 166 <span type="species:ncbi:9606">patients</span>
To validate a correlation between SMN2 gene methylation and the disease severity we analysed fibroblasts cell lines derived from independent SMN1-deleted SMA patients, also carrying two SMN2 copies. Repeated quantification of CpG methylation levels at nt positions -296 and -290 (both SMN2CGI 2) corroborated a significant correlation between CpG methylation and disease severity in type I (ML17), type IIIa (ML22) and type IIIb SMA fibroblasts (ML74) (Fig. 4A). No significant differences were observed at the remaining five positions (-871, -695, +855, +988, +1103, data not shown) demonstrated to be differentially methylated in DNA isolated from blood (Fig. 3C). Given the fact that the nearby CpG dinucleotides at nt positions -296 and -290 co-localize with the first TSS of SMN2 located at nt position -296, it appears evident that methylation levels at these sites modulate the expression of SMN2 transcripts derived from this TSS (subsequently designated as the long transcript SMN2, LT-SMN2). Using different primer combinations which specifically amplify LT-SMN2, an inverse correlation between -296 and -290 methylation levels and LT-SMN2 transcript levels was observed in type I, type IIIa and type IIIb SMA fibroblast cell lines (Fig. 4B and C). However, no significant differences in total SMN2 protein levels were detected in ML17, ML22 and ML74 fibroblasts due to the finding that LT-SMN2 transcripts account for <5% of total SMN2 transcripts in these cells (data not shown).
###end p 19
###begin p 20
###xml 4 32 4 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">survival motor neuron gene 2</italic>
###xml 34 38 34 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 166 167 166 167 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 279 283 277 281 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN1</italic>
###xml 318 322 316 320 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 561 562 559 560 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 573 574 571 572 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 586 587 584 585 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 597 598 595 596 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 931 935 929 933 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 997 1004 995 1002 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LT-SMN2</italic>
###xml 1094 1095 1092 1093 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 1177 1181 1174 1178 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDK4</italic>
###xml 1311 1312 1308 1309 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 1329 1336 1326 1333 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LT-SMN2</italic>
###xml 1422 1429 1418 1425 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LT-SMN2</italic>
###xml 1429 1438 1425 1434 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;279,&#8722;128</sup>
###xml 1507 1514 1501 1508 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LT-SMN2</italic>
###xml 296 304 <span type="species:ncbi:9606">patients</span>
###xml 489 497 <span type="species:ncbi:9606">patients</span>
Low survival motor neuron gene 2 (SMN2) methylation levels at the positions -296 and -290 are associated with mild spinal muscular atrophy (SMA) in SMA fibroblasts. (A) Bar chart showing the mean methylation levels (+/-SEM) at positions -296 and -290 in fibroblasts derived from SMN1-deleted SMA patients carrying two SMN2 copies. At both sites, type I SMA fibroblasts (ML17) show significantly higher methylation levels than fibroblasts derived from type IIIa (ML22) and type IIIb (ML74) patients. Three levels of statistical significance were discriminated: *P < 0.05, **P < 0.01, ***P < 0.001 (t-test). Methylation levels at positions -296 and -290 correlate with the activity of the transcriptional start site (TSS) at position -296 in SMA fibroblasts. Relative to type I SMA fibroblasts (ML17), the low methylation levels at positions -296 and -290 observed in type IIIa and type IIIb SMA fibroblasts are associated with high SMN2 transcripts levels originated from the TSS at position -296 (LT-SMN2) as shown by semi-quantitative RT-PCR analyses using two different primer combinations. (B) ss-Actin primers were used as internal control to verify equal loading of cDNA. CDK4 primers were used to detect potential contaminations with genomic DNA (amplicon size cDNA: 262 bp, amplicon size gDNA: 420 bp). (C) Differences in LT-SMN2 expression levels were confirmed by real-time PCR (normalized to ss-actin) using the LT-SMN2-279,-128 primer pair. Data are given as mean percentage (+/-SEM) relative to LT-SMN2 transcript levels in type I SMA fibroblasts (ML17) which were set to 100%.
###end p 20
###begin title 21
###xml 34 41 34 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LT-SMN2</italic>
HDAC inhibitor treatment bypasses LT-SMN2 gene silencing mediated by DNA methylation
###end title 21
###begin p 22
###xml 56 60 56 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 81 82 81 82 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN357F1">1</xref>
###xml 130 134 130 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 262 267 262 267 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 270 272 270 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN357C26">26</xref>
###xml 524 531 524 531 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LT-SMN2</italic>
###xml 554 555 554 555 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN357F4">4</xref>
###xml 846 853 846 853 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LT-SMN2</italic>
###xml 942 949 942 949 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LT-SMN2</italic>
###xml 999 1000 999 1000 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN357F5">5</xref>
###xml 1060 1067 1060 1067 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LT-SMN2</italic>
###xml 1125 1129 1125 1129 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1185 1186 1181 1182 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 1248 1255 1232 1239 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LT-SMN2</italic>
###xml 1288 1292 1272 1276 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1317 1318 1301 1302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN357F5">5</xref>
###xml 1523 1531 1507 1515 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1533 1535 1517 1519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN357C32">32</xref>
###xml 1833 1840 1817 1824 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LT-SMN2</italic>
###xml 1889 1890 1873 1874 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN357F5">5</xref>
###xml 1955 1962 1939 1946 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LT-SMN2</italic>
###xml 2217 2218 2201 2202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN357F6">6</xref>
###xml 2236 2242 2220 2226 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LT-SMN</italic>
###xml 2272 2276 2256 2260 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN1</italic>
###xml 2280 2284 2264 2268 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 2383 2385 2367 2369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN357C33">33</xref>
###xml 2414 2420 2398 2404 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LT-SMN</italic>
###xml 2484 2485 2468 2469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN357F6">6</xref>
###xml 2502 2503 2486 2487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN357F6">6</xref>
###xml 2567 2568 2551 2552 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN357F6">6</xref>
###xml 2686 2687 2670 2671 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN357F6">6</xref>
###xml 2116 2121 <span type="species:ncbi:9606">human</span>
Based on the observation that DNA methylation restricts SMN2 gene activity (Fig. 1A and B), we hypothesized that the abolition of SMN2 gene silencing conferred by DNA methylation might represent a promising strategy for pharmacologic SMA therapy. In 1998, Jones et al. (26) have shown that the experimental pan-HDAC inhibitor TSA is able to bypass gene silencing mediated by DNA methylation. To address this issue, type I SMA fibroblasts (ML17) showing high methylation levels at positions -296 and -290 associated with low LT-SMN2 mRNA expression (Fig. 4) were treated with effective doses of highly potent HDAC inhibitors of different chemical classes. Specifically, cells were exposed to SAHA, M344, scriptaid, oxamflatin (hydroxamic acids), or romidepsin (FK-228, cyclic tetrapeptide) for 48 h. All five test compounds dramatically increased LT-SMN2 transcript levels dose dependently, indicating that HDAC inhibitors are able to relieve LT-SMN2 gene silencing mediated by DNA methylation (Fig. 5A and B). In all analyses, the dose-dependent inductions of LT-SMN2 expression were associated with robustly increased total SMN2 transcript levels. For example, treatment with 30 microm doses of SAHA results in a approximately25-fold induction of LT-SMN2 and a 5-fold induction of total SMN2 transcript levels (Fig. 5B). However, the hitherto analysed HDAC inhibitors possess negligible HDAC isoenzyme selectivities and concordantly we previously have shown that these compounds are able to fully antagonize HDAC activity in vitro (32). Thus, we next assessed whether isoenzyme selective HDAC inhibitors such as MS-275 as well as VPA and PB, which are both under clinical evaluation for SMA therapy, show similar effects. Interestingly, neither the benzamide MS-275 nor the fatty acids VPA and PB were able to substantially elevate LT-SMN2 transcript levels even at excessive doses (Fig. 5B), indicating that MS-275, VPA and PB were not able to overcome LT-SMN2 gene silencing conferred by DNA methylation in this experimental setting. To confirm these findings in a neuroectodermal tissue we subsequently employed human hippocampal brain slice cultures (OHSCs) derived from epilepsy surgery (four individuals, Fig. 6A-D). Even though LT-SMN transcripts derived from the SMN1 or SMN2 genes were not distinguishable in this experimental paradigm due to identical promoter sequences (33), a pronounced induction of LT-SMN transcription was observed following treatment with M344 (Fig. 6A) or SAHA (Fig. 6B and C), while VPA again had no or only moderate effects (Fig. 6B-D). A dose-dependent induction of SMN expression following treatment with M344 was confirmed on protein level (Fig. 6A).
###end p 22
###begin p 23
###xml 56 63 56 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LT-SMN2</italic>
###xml 266 273 266 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LT-SMN2</italic>
###xml 367 368 367 368 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 450 457 449 456 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LT-SMN2</italic>
###xml 468 472 467 471 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 615 616 614 615 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 618 625 617 624 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LT-SMN2</italic>
###xml 636 640 635 639 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 775 782 771 778 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LT-SMN2</italic>
###xml 793 797 789 793 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
Histone deacetylase (HDAC) inhibitor treatment bypasses LT-SMN2 gene silencing mediated by DNA methylation. Treatment of type I SMA (spinal muscular atrophy) fibroblasts (ML17) with increasing doses of SAHA (hydroxamic acid) or FK-228 (cyclic tetrapeptide) elevates LT-SMN2 transcript levels in a dose-dependent manner as shown by semi-quantitative RT-PCR analyses. (A) ss-Actin primers were used as internal control to verify equal loading of cDNA. LT-SMN2 and total SMN2 transcript levels in type I SMA fibroblasts (ML17) following treatment with HDAC inhibitors for 48 h were further analysed by real-time PCR. (B) LT-SMN2 and total SMN2 transcript levels (both normalized to ss-actin) following HDAC inhibitor treatment are given as mean percentages (+/-SEM) relative to LT-SMN2 and total SMN2 transcript levels in solvent- and time-matched controls which were set to 100%.
###end p 23
###begin p 24
###xml 56 62 56 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LT-SMN</italic>
###xml 138 141 138 141 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A&#8211;D</bold>
###xml 162 168 162 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LT-SMN</italic>
###xml 202 205 202 205 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN</italic>
###xml 372 378 372 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LT-SMN</italic>
###xml 389 392 389 392 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN</italic>
###xml 492 498 489 495 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LT-SMN</italic>
###xml 509 512 506 509 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN</italic>
###xml 658 661 655 658 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN</italic>
###xml 735 736 727 728 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 758 759 744 745 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 782 783 762 763 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 980 981 958 959 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 990 991 968 969 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 77 82 <span type="species:ncbi:9606">human</span>
###xml 228 233 <span type="species:ncbi:9606">human</span>
###xml 628 635 <span type="species:ncbi:9606">patient</span>
###xml 816 821 <span type="species:ncbi:9606">human</span>
HDAC (histone deacetylase) inhibitor treatment elevates LT-SMN expression in human organotypic hippocampal brain slice cultures (OHSCs). (A-D) Bar charts showing LT-SMN and total survival motor neuron (SMN) transcript levels in human OHSCs derived from four different individuals. OHSCs were treated with the indicated doses of M344, SAHA or VPA (valproic acid) for 48 h. LT-SMN and total SMN transcript levels (both normalized to ss-actin) are given as mean percentages (+/-SEM) relative to LT-SMN and total SMN transcript levels in solvent- and time-matched controls which were set to 100%. Using OHSCs derived from the first patient (A), a dose-dependent SMN induction was confirmed on protein level (relative to ss-tubulin; 8 microm: 138 +/- 2%; 16 microm: 188 +/- 30%; 32 microm: 219 +/- 41%). A representative human OHSC and a representative western blot analysis are shown. Induction of SMN protein expression by M344 reached levels of significance at all indicated doses (P < 0.05, t-test).
###end p 24
###begin title 25
###xml 16 23 16 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LT-SMN2</italic>
###xml 97 101 97 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
Transcriptional LT-SMN2 induction by HDAC inhibitors is not mediated by DNA-demethylation of the SMN2 gene
###end title 25
###begin p 26
###xml 87 94 87 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LT-SMN2</italic>
###xml 255 257 255 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN357C34">34</xref>
###xml 258 260 258 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN357C36">36</xref>
###xml 365 372 365 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 374 376 374 376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN357C37">37</xref>
###xml 377 379 377 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN357C38">38</xref>
###xml 424 431 424 431 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LT-SMN2</italic>
###xml 547 551 547 551 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 547 551 547 551 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 649 650 645 646 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 727 734 723 730 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LT-SMN2</italic>
###xml 745 749 741 745 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 774 775 770 771 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN357F5">5</xref>
###xml 815 819 811 815 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 815 819 811 815 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 913 914 909 910 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN357F7">7</xref>
###xml 1034 1038 1030 1034 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1034 1038 1030 1034 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 1064 1065 1060 1061 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN357F7">7</xref>
###xml 1122 1126 1118 1122 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1122 1126 1118 1122 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 1232 1239 1228 1235 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LT-SMN2</italic>
###xml 1264 1265 1260 1261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN357F7">7</xref>
###xml 1318 1325 1314 1321 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LT-SMN2</italic>
###xml 1399 1403 1395 1399 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
The mechanism by which pan-HDAC inhibitors such as SAHA and romidepsin (FK-228) bypass LT-SMN2 silencing by DNA methylation remains elusive. In single cell cultures, TSA and VPA have shown to trigger DNA demethylation in a replication-independent manner (34-36) and gene-specific DNA demethylating activities of VPA, MS-275 and TSA have subsequently been confirmed in vivo (37,38). To assess whether HDAC inhibitors elevate LT-SMN2 transcript levels due to their propensity to promote DNA demethylation, we next analysed the methylation levels of SMN2CGI 2 in type I SMA fibroblasts (ML17) following HDAC inhibitor treatment for 48 h. Using 10 microm doses of SAHA, this experimental setting has shown to substantially elevate LT-SMN2 and total SMN2 transcript levels (Fig. 5A and B). However, SAHA did not promote SMN2CGI 2 demethylation and neither did VPA or PB as shown by bisulphite genomic sequencing (Fig. 7A). In contrast, treatment of ML17 cells with zebularine, a DNA-demethylating drug structurally related to Aza, induced SMN2CGI 2 demethylation (Fig. 7A and B), and consistent with previous findings, reduced SMN2CGI 2 methylation levels including the nt positions -296 and -290 associated with significantly increased LT-SMN2 transcript levels (Fig. 7B and C). These results suggest that transcriptional LT-SMN2 induction by HDAC inhibitors is not mediated by DNA-demethylation of the SMN2 gene promoter.
###end p 26
###begin p 27
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LT-SMN2</italic>
###xml 78 106 78 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">survival motor neuron gene 2</italic>
###xml 108 112 108 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 139 140 139 140 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 241 242 241 242 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 269 270 269 270 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 289 290 285 286 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 316 320 312 316 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 316 320 312 316 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 429 433 425 429 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 429 433 425 429 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 580 581 572 573 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 644 648 636 640 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 644 648 636 640 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 857 864 849 856 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LT-SMN2</italic>
###xml 939 940 927 928 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 1034 1038 1022 1026 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1034 1038 1022 1026 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 1088 1089 1076 1077 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 1103 1107 1091 1095 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1103 1107 1091 1095 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 1156 1163 1144 1151 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LT-SMN2</italic>
###xml 1211 1218 1199 1206 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LT-SMN2</italic>
###xml 1313 1320 1298 1305 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LT-SMN2</italic>
###xml 1391 1392 1376 1377 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 1422 1427 1407 1412 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MeCP2</italic>
###xml 1437 1444 1422 1429 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LT-SMN2</italic>
###xml 1489 1490 1474 1475 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 1492 1497 1477 1482 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MeCP2</italic>
###xml 1502 1509 1487 1494 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LT-SMN2</italic>
###xml 1604 1609 1586 1591 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MeCP2</italic>
###xml 1613 1620 1595 1602 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LT-SMN2</italic>
###xml 1807 1811 1789 1793 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1875 1876 1857 1858 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
###xml 1878 1879 1860 1861 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</bold>
###xml 1887 1891 1869 1873 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN1</italic>
###xml 1968 1972 1950 1954 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 2115 2119 2097 2101 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 2302 2303 2280 2281 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 2368 2372 2346 2350 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 2420 2424 2398 2402 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 2443 2444 2421 2422 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</bold>
###xml 2535 2539 2513 2517 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 2782 2783 2760 2761 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 2794 2795 2772 2773 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 2807 2808 2785 2786 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 2818 2819 2796 2797 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 2200 2206 <span type="species:ncbi:9986">rabbit</span>
LT-SMN2 induction by HDAC (histone deacetylase) inhibitors is not mediated by survival motor neuron gene 2 (SMN2) promoter demethylation. (A) Treatment of type I spinal muscular atrophy (SMA) fibroblasts (ML17) with valproic acid (VPA) (10 mm), phenylbutyrate (PB) (1 mm) or SAHA (10 microm) for 48 h did not affect SMN2CGI 2 methylation levels. Frequency plot illustrating methylation levels of each CpG dinucleotide within the SMN2CGI 2 in treated ML17 cells compared with time- and solvent-matched ML17 control fibroblasts. The DNA-demethylating drug zebularine (ZEB, 100 microm) was used as positive control. The mean methylation levels of SMN2CGI 2, indicated by horizontal lines, are as follows - control: 47.0%, VPA: 44.5%, PB 44.1%, SAHA: 45.0%, ZEB: 37.3%. Demethylation of CpG dinucleotides at positions -296 and -290 is associated with increased LT-SMN2 expression. Treatment of type I SMA fibroblasts (ML17) with ZEB (100 microm, 48 h) results in a significant demethylation of nine out of 12 CpG dinucleotides located in SMN2CGI 2, including the nt positions -296 and -290. (B) ZEB-induced SMN2CGI 2 demethylation is associated with increased LT-SMN2 levels as shown by quantitative real-time PCR. LT-SMN2 transcript levels (normalized to ss-actin) are given as mean percentages (+/-SEM) relative to LT-SMN2 expression levels in solvent- and time-matched controls set to 100%. (C) siRNA-mediated knockdown of MeCP2 elevates LT-SMN2 transcript levels in ML17 SMA fibroblasts. (D) MeCP2 and LT-SMN2 transcript levels (normalized to ss-actin) are given as mean percentages (+/-SEM) relative to MeCP2 or LT-SMN2 expression levels in time-matched controls transfected with AllStars negative control siRNA. The transcriptional co-repressor methyl-CpG-binding-protein 2 (MeCP2) is associated with the SMN2 promoter region and binds in a methylation-dependent fashion. (E, F) Using SMN1-deleted SMA fibroblasts cells (ML17), a significant binding of MeCP2 to the SMN2 promoter region was observed by chromatin immunoprecipitation (ChIP) analysis using an anti-MeCP2 antibody and primers amplifying the genomic SMN2 promoter region from nt -372 to -266. An unrelated antibody (negative Ctrl IgG, rabbit, Diagenode) was used as negative control. Treatment of ML17 SMA fibroblast cells with 100 microm ZEB resulted in a significant reduction of MeCP2 binding to the SMN2 promoter region. MeCP2 is enriched at a 286 bp SMN2 promoter region. (G) ChIP analyses using ML17 fibroblasts and six different primer pairs covering the genomic SMN2 promoter region from nt -631 to +59. Enrichment after MeCP2 ChIP was detectable for all primer pairs while two primer pairs showed considerably higher ChIP-PCR signal intensities. Three levels of statistical significance were discriminated: *P < 0.05, **P < 0.01, ***P < 0.001 (t-test).
###end p 27
###begin title 28
###xml 45 49 45 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 88 95 88 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LT-SMN2</italic>
Transcriptional repressor MeCP2 binds to the SMN2 promoter and mediates transcriptional LT-SMN2 silencing
###end title 28
###begin p 29
###xml 97 99 97 99 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN357C39">39</xref>
###xml 409 413 409 413 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 467 468 467 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN357F7">7</xref>
###xml 495 502 495 502 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LT-SMN2</italic>
###xml 543 544 543 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN357F5">5</xref>
###xml 549 550 549 550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN357F6">6</xref>
###xml 597 601 597 601 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 895 897 895 897 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN357C27">27</xref>
###xml 1062 1064 1062 1064 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN357C26">26</xref>
###xml 1065 1067 1065 1067 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN357C27">27</xref>
###xml 1112 1116 1112 1116 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1250 1257 1250 1257 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LT-SMN2</italic>
###xml 1318 1319 1318 1319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN357F7">7</xref>
###xml 1356 1363 1356 1363 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LT-SMN2</italic>
###xml 1431 1435 1431 1435 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1516 1520 1516 1520 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1516 1520 1516 1520 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 1639 1643 1639 1643 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1690 1691 1690 1691 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN357F7">7</xref>
###xml 1704 1711 1704 1711 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LT-SMN2</italic>
###xml 1792 1793 1792 1793 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN357F7">7</xref>
###xml 1855 1859 1855 1859 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1875 1876 1875 1876 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN357F7">7</xref>
###xml 1917 1921 1917 1921 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1987 1994 1987 1994 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LT-SMN2</italic>
###xml 2063 2064 2063 2064 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN357F7">7</xref>
###xml 2118 2122 2118 2122 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 2148 2149 2146 2147 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 2158 2159 2156 2157 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 2265 2269 2263 2267 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 2299 2306 2297 2304 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LT-SMN2</italic>
###xml 2367 2371 2365 2369 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 2493 2497 2491 2495 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 2551 2555 2549 2553 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 2551 2555 2549 2553 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 2660 2661 2658 2659 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN357F7">7</xref>
###xml 2864 2868 2862 2866 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 3033 3037 3031 3035 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
Two basic models evolved regarding the mechanism by which DNA methylation affects transcription (39). DNA methylation can directly repress transcription by blocking transcriptional activators from binding to cognate DNA sequences, alternatively methyl-CpG DNA-binding proteins (MBPs) recognize methylated DNA and recruit co-repressors to silence gene expression directly. Since HDAC inhibitors do not promote SMN2 gene demethylation in our experimental setting (Fig. 7A), and are able to bypass LT-SMN2 gene silencing by DNA methylation (Figs 5 and 6), we hypothesized that DNA methylation at the SMN2 promoter region is recognized by an MBP which recruits HDAC activity to mediate epigenetic gene silencing. Previous studies revealed that two global mechanisms of epigenetic gene regulation, DNA methylation and histone deacetylation, can be linked by the methyl-CpG-binding-protein 2 (MeCP2) (27). MeCP2 is an abundant chromosomal protein that specifically binds to methylated DNA and requires HDAC activity to repress transcription from methylated promoters (26,27). Thus, we hypothesized that the methylated SMN2 promoter is recognized by MeCP2. In line with this hypothesis, siRNA-mediated knockdown of MeCP2 resulted in significantly increased LT-SMN2 transcript levels in ML17 type I SMA fibroblast cells (Fig. 7D). To validate the role of MeCP2 in LT-SMN2 expression, we next analysed the potential binding of MeCP2 to the SMN2 promoter region by chromatin immunoprecipitation (ChIP). Initial analyses using SMN2CGI 2-specific primers covering the genomic region from nt -372 to -266 revealed a clear association of MeCP2 with the SMN2 promoter region in ML17 SMA fibroblasts (Fig. 7E). Elevated LT-SMN2 transcript levels following treatment of ML17 fibroblasts with zebularine (Fig. 7C) are associated with a decrease in the MeCP2 binding to the SMN2 promoter (Fig. 7F), indicating that MeCP2 recognizes the SMN2 promoter in a methylation-dependent fashion. Moreover, increased LT-SMN2 transcript levels following siRNA-mediated knockdown of MeCP2 (Fig. 7D) are associated with decreased MeCP2 binding to the SMN2 promoter (77.8 +/- 4.6%, P < 0.05, t-test). These data indicate a methylation-dependent binding of the transcriptional repressor MeCP2 to the SMN2 promoter region resulting in LT-SMN2 silencing. To determine the binding pattern of MeCP2 on the SMN2 promoter we performed MeCP2 ChIP analyses using ML17 SMA fibroblasts and six different primer pairs covering the genomic SMN2 promoter region from nt -631 to +59, which comprises SMN2CGI 2 (nt -469 to -247) and adjacent sequences. Although MeCP2 binding was detectable in all cases (Fig. 7G), ChIP-PCR signal intensities were substantially higher at the genomic region from nt -349 and -63, suggesting enrichment at this site. This particular 286 bp region contains all three transcriptional SMN2 start sites at positions -296, -242 and -163 and the differentially methylated CpG dinucleotides at positions -296 and -290, suggesting a probable role of MeCP2 in SMN2 gene silencing.
###end p 29
###begin title 30
DISCUSSION
###end title 30
###begin p 31
###xml 38 42 38 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 229 233 229 233 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 254 255 254 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN357F1">1</xref>
###xml 268 269 268 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN357F7">7</xref>
###xml 293 297 293 297 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 327 331 327 331 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 327 331 327 331 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 448 449 448 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN357F2">2</xref>
###xml 536 540 536 540 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN1</italic>
###xml 573 577 573 577 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 573 577 573 577 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 587 591 587 591 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 587 591 587 591 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 620 624 620 624 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 620 624 620 624 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 676 680 676 680 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 676 680 676 680 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 731 732 731 732 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN357F2">2</xref>
###xml 745 746 745 746 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN357F3">3</xref>
###xml 818 820 818 820 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN357C29">29</xref>
###xml 830 834 830 834 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 830 834 830 834 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 937 941 937 941 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 937 941 937 941 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 975 979 975 979 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 975 979 975 979 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 1016 1020 1016 1020 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1016 1020 1016 1020 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 1126 1128 1126 1128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN357C40">40</xref>
###xml 1167 1171 1167 1171 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1167 1171 1167 1171 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 1192 1196 1192 1196 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1192 1196 1192 1196 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 1349 1351 1349 1351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN357C40">40</xref>
###xml 1363 1367 1363 1367 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1363 1367 1363 1367 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 1459 1463 1459 1463 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1459 1463 1459 1463 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 1501 1505 1501 1505 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1501 1505 1501 1505 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 1518 1522 1518 1522 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1518 1522 1518 1522 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 1535 1539 1535 1539 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1535 1539 1535 1539 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 1582 1584 1582 1584 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN357C29">29</xref>
###xml 1615 1616 1615 1616 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN357F2">2</xref>
###xml 1629 1630 1629 1630 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN357F3">3</xref>
###xml 1700 1702 1700 1702 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN357C40">40</xref>
###xml 1715 1719 1715 1719 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1843 1845 1843 1845 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN357C41">41</xref>
###xml 1926 1930 1926 1930 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1926 1930 1926 1930 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 1938 1940 1938 1940 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN357C29">29</xref>
###xml 1958 1962 1958 1962 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1958 1962 1958 1962 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 2060 2064 2060 2064 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 2060 2064 2060 2064 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 553 561 <span type="species:ncbi:9606">patients</span>
###xml 1802 1807 <span type="species:ncbi:9606">human</span>
Here, we show for the first time that SMN2, the major disease modifier and target gene for pharmacological SMA treatment, is epigenetically regulated by DNA methylation given by the fact that DNA-demethylating compounds increase SMN2 gene activity (Figs 1A and B, and 7C). We demonstrate that SMN2 contains four putative CGIs (SMN2CGIs) located within the genomic region 896 nt upstream and 1146 nt downstream of its translational start site (Fig. 2A). Analysis of DNA isolated from fibroblast cell lines and blood samples derived from SMN1-deleted SMA patients identified SMN2CGI 1 and SMN2CGI 4 to be hypermethylated, SMN2CGI 3 appeared to be almost methylation-free, while SMN2CGI 2 showed intermediate methylation levels (Figs 2B and C, and 3A-C). Since CGIs are usually defined as short unmethylated DNA patches (29), solely SMN2CGI 3 (446 bp, GC content 62.1%) can be regarded as a 'classical' CGI. However, recent data categorize SMN2CGI 1 (252 bp, GC content 54.8%), SMN2CGI 2 (223 bp, GC content 58.3%) and SMN2CGI 4 (303 bp, GC content 59.4%) as 'weak' CGIs due to their small size and comparatively low GC content (40). Differences between the 'classical' SMN2CGI 3 and the 'weak' SMN2CGIs 1, 2 and 4 become more apparent when calculating the CpG density, which is defined as the ratio between observed versus expected CpG dinucleotides (40). Although SMN2CGI 3 possesses a high CpG density (0.94) usually found in unmethylated CGIs, the remaining SMN2CGIs show intermediate CpG densities (SMN2CGI 1: 0.74, SMN2CGI 2: 0.79, SMN2CGI 4: 0.79) characteristic for weak CGIs (29). In line with our data (Figs 2B and C, and 3A and B), weak CGIs usually show high frequencies of DNA methylation (40). Moreover, SMN2 appears to be a typical gene regarding its CGI distribution. Approximately 70% of human genes are linked to promoter CGIs (41) and about half of all CGIs were found at the TSS of an annotated gene (such as SMN2CGI 2) (29). Among the four SMN2CGIs analysed, we provide first evidence that particularly the genomic region comprising the weak SMN2CGI 2 is functionally important regarding SMA disease progression and pharmacological SMA therapy.
###end p 31
###begin p 32
###xml 12 16 12 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 166 170 166 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN1</italic>
###xml 185 189 185 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 204 205 204 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN357C9">9</xref>
###xml 206 208 206 208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN357C42">42</xref>
###xml 234 238 234 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 269 273 269 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN1</italic>
###xml 397 398 397 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN357C9">9</xref>
###xml 399 401 399 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN357C42">42</xref>
###xml 446 450 446 450 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 778 782 778 782 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 778 782 778 782 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 794 795 794 795 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN357F3">3</xref>
###xml 801 802 801 802 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN357F4">4</xref>
###xml 844 848 844 848 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1107 1111 1107 1111 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1138 1139 1138 1139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN357F2">2</xref>
###xml 1270 1274 1270 1274 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1281 1282 1281 1282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN357F4">4</xref>
###xml 1291 1292 1291 1292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN357F7">7</xref>
###xml 1386 1393 1386 1393 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LT-SMN2</italic>
###xml 1454 1458 1454 1458 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1551 1558 1551 1558 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LT-SMN2</italic>
###xml 1580 1587 1580 1587 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LT-SMN2</italic>
###xml 1625 1629 1625 1629 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1720 1727 1720 1727 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LT-SMN2</italic>
###xml 1810 1817 1810 1817 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LT-SMN2</italic>
###xml 1828 1832 1828 1832 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1924 1928 1924 1928 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1935 1938 1935 1938 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Smn</italic>
###xml 1938 1941 1938 1941 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1941 1945 1941 1945 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1945 1948 1945 1948 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 1951 1953 1951 1953 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN357C43">43</xref>
###xml 1997 2001 1997 2001 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 2169 2171 2169 2171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN357C19">19</xref>
###xml 2185 2192 2185 2192 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LT-SMN2</italic>
###xml 2409 2416 2409 2416 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LT-SMN2</italic>
###xml 2581 2585 2581 2585 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN1</italic>
###xml 2678 2680 2678 2680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN357C44">44</xref>
###xml 2817 2826 2817 2826 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Plastin 3</italic>
###xml 2867 2869 2867 2869 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN357C45">45</xref>
###xml 2959 2961 2959 2961 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN357C44">44</xref>
###xml 327 335 <span type="species:ncbi:9606">patients</span>
###xml 679 687 <span type="species:ncbi:9606">patients</span>
###xml 702 710 <span type="species:ncbi:9606">patients</span>
###xml 1889 1904 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1918 1923 <span type="species:ncbi:9606">human</span>
Even though SMN2 has been identified as the major SMA disease modifier, differences in disease progression have frequently been observed in the presence of identical SMN1 mutations and SMN2 copy numbers (9,42). In the presence of two SMN2 copies, homozygous absence of SMN1 causes type I SMA in approximately two-thirds of all patients, while milder phenotypes are consequently also quite common (9,42). These findings led to the hypothesis that SMN2 genes are not functionally equivalent. Using DNA derived from comparatively easily accessible sources such as blood and skin we identified significantly lower methylation levels at two adjacent CpG dinucleotides in type III SMA patients compared with patients suffering from severe type I SMA (nt positions -296 and -290, both SMN2CGI 2, Figs 3C and 4A), suggesting that the capability of the SMN2 gene copies to counteract SMA disease progression is modulated by DNA methylation. The functional relevance of DNA methylation at nt positions -296 and -290 is further highlighted by the finding that these CpG dinucleotides co-localize with the first TSS of SMN2 at nt position -296 (Fig. 2A). We demonstrate that methylation levels at nt positions -296 and -290 inversely correlate with the activity of the first TSS of SMN2 (Figs 4A-C, and 7B and C) indicating that DNA methylation at these nt positions is linked with transcriptional LT-SMN2 silencing. In summary, our data provide first evidence that SMN2 gene copies are not functionally equivalent due to differences in DNA methylation affecting LT-SMN2 expression. However, LT-SMN2 contributes only moderately to total SMN2 transcript levels in SMA fibroblasts (described earlier). To address the question whether LT-SMN2 expression is regulated in a tissue-dependent fashion, we subsequently quantified LT-SMN2 and total SMN2 transcript levels in various tissues derived from adult transgenic mice carrying the human SMN2 gene (Smn-/-SMN2+/+) (43). Consistent with previous findings, total SMN2 transcript levels are higher in CNS tissues such as cerebrum and spinal cord compared with mesodermal and endodermal tissues such as skeletal muscle, heart and liver (19). Similarly, LT-SMN2 transcripts display considerably higher expression levels in CNS tissues with a >3-fold higher expression in spinal cord compared with muscle, heart and liver, suggesting that the amounts of SMN protein derived from LT-SMN2 are sufficient to modulate motor neuron degradation (). However, SMA disease severities appear to be modified by multiple mechanisms. In rare cases, haploidentical SMN1-deleted siblings show highly discordant SMA phenotypes ranging from affected to unaffected (44). In these families it has been shown that the SMA phenotype can be influenced by elevated expression of an independent modifying gene, Plastin 3, which protects against SMA in females (45). Exemplary analysis of nt positions -296 and -290 in two of these families (#34, #482) (44) revealed no differences in DNA methylation between haploidentical affected and unaffected individuals (data not shown).
###end p 32
###begin p 33
###xml 141 148 141 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LT-SMN2</italic>
###xml 405 407 405 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN357C26">26</xref>
###xml 408 410 408 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN357C27">27</xref>
###xml 621 628 621 628 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LT-SMN2</italic>
###xml 669 670 669 670 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN357F5">5</xref>
###xml 694 695 694 695 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN357F6">6</xref>
###xml 744 748 744 748 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 876 877 876 877 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN357F5">5</xref>
###xml 882 883 882 883 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN357F6">6</xref>
###xml 1084 1088 1084 1088 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1709 1711 1709 1711 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN357C46">46</xref>
###xml 676 681 <span type="species:ncbi:9606">human</span>
###xml 1635 1643 <span type="species:ncbi:9606">patients</span>
Despite the apparent correlation between the CpG methylation levels at nt positions -296 and -290 and the disease severity, the finding that LT-SMN2 expression is silenced by DNA methylation is especially important regarding pharmacological SMA therapy using HDAC inhibitors. The fundamental mechanisms of epigenetic gene regulation, DNA methylation and histone acetylation, have shown to be interlinked (26,27). Consistent with these findings we demonstrate that a panel of five pan-HDAC inhibitors including the hydoxamic acid vorinostat (SAHA) as well as the cyclic tetrapeptide romidepsin (FK-228) are able to bypass LT-SMN2 gene silencing in SMA fibroblasts (Fig. 5) and human OHSCs (Fig. 6), resulting in up to 5-fold inductions of total SMN2 transcript levels. In contrast, the HDAC isoenzyme selective inhibitors MS-275, VPA and PB display only moderate effects (Figs 5 and 6). These findings highlight functional differences between HDAC inhibitors regarding pharmacological SMA therapy and suggest that pan-HDAC inhibitors possess superior functional capacities to activate SMN2. Given the fact that the pan-HDAC inhibitors vorinostat (SAHA) and romidepsin (FK-228) are either FDA approved or under clinical phase II evaluation for cancer treatment, our data further highlight that these readily available compounds might be considered as candidate drugs for SMA therapy in case the ongoing clinical trials using VPA or PB do not show the desired efficacies. Especially vorinostat appears to be promising due to the fact that this molecule has shown to cross the blood-brain barrier and ongoing clinical evaluation in cancer patients exemplifies a good oral bioavailability and biological activity (46).
###end p 33
###begin p 34
###xml 37 44 37 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LT-SMN2</italic>
###xml 217 221 217 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 296 300 296 300 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 441 442 441 442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN357F7">7</xref>
###xml 465 469 465 469 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 527 528 527 528 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN357F7">7</xref>
###xml 559 566 559 566 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LT-SMN2</italic>
###xml 589 590 589 590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DDN357F7">7</xref>
###xml 677 679 677 679 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN357C26">26</xref>
###xml 680 682 680 682 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN357C47">47</xref>
###xml 763 767 763 767 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 975 977 975 977 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN357C32">32</xref>
###xml 1027 1034 1027 1034 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LT-SMN2</italic>
###xml 1063 1070 1063 1070 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LT-SMN2</italic>
###xml 1282 1289 1282 1289 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LT-SMN2</italic>
###xml 1385 1392 1385 1392 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LT-SMN2</italic>
Moreover, we provide evidence of how LT-SMN2 gene silencing by DNA methylation is regulated. ChIP experiments using ML17 SMA fibroblasts revealed that the methyl-CpG-binding protein 2 (MeCP2) is localized at a 286 bp SMN2 promoter region (nt -349 to -63) containing all the three transcriptional SMN2 start sites at nt positions -296, -242 and -163 as well as the differentially methylated CpG dinucleotides at positions -296 and -290 (Fig. 7G). MeCP2 binds to the SMN2 promoter region in a methylation-dependent fashion (Fig. 7F) and MeCP2 knockdown induced LT-SMN2 mRNA expression (Fig. 7D). Following binding to methylated DNA, MeCP2 is known to recruit HDACs to chromatin (26,47), suggesting that the regulatory component MeCP2 might be involved in mediating SMN2 gene silencing by DNA methylation. Since the isoenzyme selective HDAC inhibitors MS-275 and VPA have shown to inhibit HDAC1, HDAC2, HDAC3 (both MS-275 and VPA) and HDAC9 (MS-275) at doses used in our study (32), the finding that these drugs do not counteract LT-SMN2 silencing suggests that the LT-SMN2 induction observed following pan-HDAC inhibitor treatment was due to inhibition of the remaining classical HDACs (HDACs 4-8, 10, 11). Thus, further analysis of the specific roles of MeCP2 and HDAC isoenzymes in LT-SMN2 expression represent important steps to develop optimized HDAC inhibitors targeted to overcome LT-SMN2 silencing.
###end p 34
###begin p 35
###xml 43 47 43 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 43 47 43 47 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>SMN2</italic></sup>
###xml 322 326 322 326 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN1</italic>
###xml 341 345 341 345 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 381 385 381 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN1</italic>
###xml 444 448 444 448 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 498 502 498 502 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN1</italic>
###xml 554 558 554 558 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 624 628 624 628 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN1</italic>
###xml 720 724 720 724 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN1</italic>
###xml 678 686 <span type="species:ncbi:9606">patients</span>
Regarding the apparent correlation between SMN2CGI 2 methylation levels and disease severity, continuative studies are mandatory to assess whether the accurate quantification of DNA methylation levels at nt positions -296 and -290 represents a valuable tool to predict SMA disease progression in the presence of identical SMN1 mutations and SMN2 copy numbers. Furthermore, initial SMN1 promoter methylation analyses of DNA samples derived from SMN2-deleted and unaffected individuals revealed that SMN1 is subject to promoter methylation very similar to SMN2 (). Based on these findings one might speculate whether aberrant SMN1 promoter methylation may be causative for SMA in patients showing at least one non-mutated SMN1 gene copy.
###end p 35
###begin title 36
MATERIALS AND METHODS
###end title 36
###begin title 37
Chemicals
###end title 37
###begin p 38
###xml 530 531 530 531 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
The following chromatin-remodelling compounds have been used: M344 (382149, Calbiochem, San Diego, CA, USA), MS-275 (382147, Calbiochem), PB (567616, Calbiochem), zebularine (691400, Calbiochem), SAHA (270-288, Axxora, Lorrach, Germany), VPA (P-4543, Sigma-Aldrich, St Louis, MO, USA), scriptaid (S7817, Sigma-Aldrich), oxamflatin (O3139, Sigma-Aldrich) and Aza (A-3656, Sigma-Aldrich). Romidepsin (FK-228) was kindly provided by Gloucester Pharmaceuticals (Cambridge, MA, USA). All test compounds were dissolved in 100% DMSO or H2O (VPA).
###end p 38
###begin title 39
###xml 4 11 <span type="species:ncbi:9606">patient</span>
SMA patient samples and DNA isolation
###end title 39
###begin p 40
###xml 126 128 126 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN357C48">48</xref>
###xml 265 267 265 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN357C49">49</xref>
###xml 381 383 381 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN357C50">50</xref>
###xml 389 393 389 393 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN1</italic>
###xml 394 398 394 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 458 459 458 459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN357C9">9</xref>
###xml 580 582 580 582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN357C14">14</xref>
###xml 43 51 <span type="species:ncbi:9606">patients</span>
###xml 74 82 <span type="species:ncbi:9606">patients</span>
Informed consent was obtained from all SMA patients or their parents. All patients fulfilled the diagnostic criteria for SMA (48); SMA disease severities (type I SMA, MIM #253300; type II SMA, MIM #253550; type IIIa/IIIb, MIM #253400) were classified as described (49). Genomic DNA was isolated from venous blood samples drawn for diagnostic purposes using the salting-out method (50) and SMN1/SMN2 gene copy numbers were determined as described previously (9). The fibroblast cell lines used in this study have been established from skin biopsies and were cultured as described (14). Fibroblasts were cultured for the indicated time spans and harvested by trypsinization. DNA was isolated from fibroblast cell cultures using the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's protocol.
###end p 40
###begin title 41
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human OHSCs
###end title 41
###begin p 42
###xml 490 492 490 492 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN357C51">51</xref>
###xml 856 858 852 854 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN357C52">52</xref>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 36 44 <span type="species:ncbi:9606">patients</span>
###xml 309 317 <span type="species:ncbi:9606">patients</span>
###xml 914 919 <span type="species:ncbi:9606">human</span>
Human hippocampi were obtained from patients with chronic intractable temporal lobe epilepsy who underwent surgical treatment in the Epilepsy Surgery Program at the Department of Neurosurgery (University of Erlangen). For scientific use of tissue specimens, informed and written consent was obtained from all patients and studies were approved by the local Ethics Committee of the University of Erlangen. Surgical specimens were prepared and processed according to the interface technique (51). In brief, hippocampal brain samples were cut into 350 microm thick horizontal slices on a vibratome (Leica Microsystems, Wetzlar, Germany). Each brain slice was transferred into culture plate insert membranes (BD Biosciences, San Jose, CA, USA) and thereafter into 6-well culture dishes (BD Biosciences) containing 1.2 ml culture medium as described in detail (52). A day after preparation, culture medium was changed, human OHSCs were exposed to the test compounds or solvent only for 48 h and snap-frozen in liquid nitrogen.
###end p 42
###begin title 43
Protein sample preparation and western blot analysis
###end title 43
###begin p 44
###xml 91 92 91 92 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 132 133 132 133 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 493 498 <span type="species:ncbi:10090">mouse</span>
###xml 570 575 <span type="species:ncbi:10090">mouse</span>
###xml 643 654 <span type="species:ncbi:3704">horseradish</span>
###xml 677 681 <span type="species:ncbi:9925">goat</span>
###xml 687 692 <span type="species:ncbi:10090">mouse</span>
Human OHSCs and fibroblast cell culture cell pellets were resuspended in RIPA buffer (150 mm NaCl, 1% NP40, 0.5% DOC, 0.1% SDS, 50 mm Tris, pH 8.0) to obtain whole cell protein extracts. Denatured protein (7.5 microg) of each sample were resolved by SDS-PAGE on 4-12% Bis-Tris Gels (Invitrogen, Carlsbad, CA, USA) and transferred to nitrocellulose membrane by overnight wet blotting. Immunostaining of the membrane was performed according to standard protocols using the following antibodies: mouse monoclonal anti-ss-tubulin (T 4026, Sigma-Aldrich, dilution 1:20 000), mouse monoclonal anti-SMN (610647, BD Biosciences, dilution 1:1,000) and horseradish peroxidase conjugated goat anti-mouse IgG (115-035-003, Dianova, dilution 1:10 000) as secondary antibody. Detection of signals was carried out using the Super Signal West Pico chemiluminescence reagent (Pierce, Rockford, IL, USA). Densitometric analyses were performed using the Quantity One 1-D Analysis Software (Bio-Rad, Hercules, CA, USA).
###end p 44
###begin title 45
RNA isolation and quantitative RT-PCR analysis
###end title 45
###begin p 46
###xml 493 495 489 490 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#223;</italic>
###xml 496 501 491 496 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">actin</italic>
###xml 605 610 598 603 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDK-4</italic>
###xml 703 710 696 703 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LT-SMN2</italic>
###xml 719 723 712 716 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;279</sup>
###xml 767 771 760 764 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;274</sup>
###xml 816 820 809 813 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;128</sup>
###xml 864 867 857 860 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+90</sup>
###xml 2115 2128 2026 2031 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;&#916;&#916;Ct</sup>
###xml 2689 2693 2591 2595 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 2795 2800 2696 2701 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MeCP2</italic>
###xml 2874 2877 2775 2778 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN</italic>
###xml 2903 2907 2804 2808 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN1</italic>
###xml 2912 2916 2813 2817 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 2986 2990 2887 2891 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 3072 3076 2973 2977 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 3102 3106 3003 3007 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN1</italic>
Isolation of total RNA was performed using the RNeasy Mini Kit and QIAshredder columns according to the manufacture's protocol (Qiagen). RNA concentrations were determined spectrophotometrically. For semiquantitative PCR analyses, reverse transcription (RT) was performed using oligo dT primers and 1 microg of total RNA by applying the SuperScript First-Strand Synthesis System (Invitrogen). Two microlitres of each RT reaction was used for each RT-PCR. cDNAs were amplified using primers of ss-actin (ss-actin-fwd: 5'-AAC GGC TCC GGC ATG TGC AA-3', ss-actin-rev: 5'-CTC AAA CAT GAT CTG GGT CAT CTT-3'), CDK-4 (CDK-4-fwd: 5'-CTA TGG GAC AGT GTA CAA GG-3', CDK-4-rev: 5'-GAT ATG TCC TTA GGT CCT GG-3'), LT-SMN2 (LT-SMN2-279-fwd: 5'-ACT CCA GCC TGA GCG ACA-3', LT-SMN2-274-fwd: 5'-AGC CTG AGC GAC AGG GCGA-3', LT-SMN2-128-rev: 5'-TCT ACG AGT GGT TAT CGC-3', LT-SMN2+90-rev: 5'-ATC ATC GCT CTG GCC TGT GCC-3'). The following PCR conditions were used: 5 min initial denaturation (95degreesC), followed by 25-37 cycles (95degreesC for 15 s, 68degreesC for 30 s and 72degreesC for 35 s and final extension step (72degreesC for 5 min). PCR products were separated on 2% agarose gels and visualized by ethidium bromide staining. For real-time quantification of target gene expression, one step RT-PCR was preformed using the QuantiTect SYBR Green RT-PCR Kit (Qiagen) on an Applied Biosystems 7500 Real-Time PCR System (Applied Biosystems, Darmstadt, Germany). Each 20 microl RT-PCR mix contained 10 ng total RNA (4 ng/microl), 2 microl of the primer dilution, 10 microl x2 QuantiTect SYBR Green RT-Master Mix and 0.2 microl QuantiTect RT Mix. One-step RT-PCR reactions were carried out in 96-well optical reaction plates, covered with Optical Adhensive Covers (Applied Biosystems). Cycling conditions were as follows: 50degreesC for 30 min (RT step), 95degreesC for 15 min and 40 cycles of 94degreesC for 15 s, 55degreesC for 30 s and 72degreesC for 35 s. Real-time RT-PCR was conducted four times for each gene and each RNA sample and results is given as mean +/- SEM. The comparative method of relative quantification (2-DeltaDeltaCt) was used to calculate the relative expression levels of each target gene (normalized to ss-actin) compared with the non-treated control samples. RT-PCR specificity of each reaction was verified by melting curve analysis and confirmed by 2% agarose gel electrophoresis. Whenever possible, amplicons have been designed to span exon borders to exclude false positive detection of genomic contaminations. The following primers have been used for quantitative real-time RT-PCR: LT-SMN2-fwd 5'-ACT CCA GCC TGA GCG ACA-3', LT-SMN2-rev 5'-TCT ACG AGT GGT TAT CGC-3'. SMN2: Quantitect primer assay QT01673679 (Qiagen), ss-actin: Quantitect primer assay QT00095431 (Qiagen), MeCP2: Quantitect primer assay QT00039361 (Qiagen). On cDNA level, full-length SMN transcripts derived from SMN1 and SMN2 are identical except for two silent nt differences in exons 7 and 8. SMN2 Quantitect primer assay QT01673679 amplifies exons 5 and 6. Please note that the SMN2 primers used also detect SMN1 when present.
###end p 46
###begin title 47
Bisulphite genomic sequencing
###end title 47
###begin p 48
###xml 134 136 134 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN357C53">53</xref>
###xml 1243 1259 1196 1212 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Escherichia coli</italic>
###xml 1730 1734 1683 1687 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN1</italic>
###xml 1739 1743 1692 1696 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SMN2</italic>
###xml 1243 1259 <span type="species:ncbi:562">Escherichia coli</span>
DNA methylation analysis was carried out by bisulphite genomic sequencing using the pyrosequencing technology as described in detail (53). Bisulphite conversion of DNA (1 microg per sample) was performed using the EpiTect Bisulfite Kit (Qiagen) according to the manufacturer's protocol. Regions of interest were amplified by nested PCR using AmpliTaq Gold (Applied Biosystems) and biotinylated fwd/rev primer for the inner PCRs. The PCR conditions were as follows: 95degreesC for 5 min, followed by 40-50 cycles (95degreesC for 15 s, 52-55degreesC for 45 s, 72degreesC for 1 min) and a final extension step of 5 min at 72degreesC. The biotinylated PCR products (25 microl) were cleaned up using Streptavidin Sepharosetrade mark High Performance (GE Healthcare, Uppsala, Sweden) and a PyroMark Vacuum Prep Workstation (Biotage, Uppsala, Sweden). The purified PCR products were used for the pyrosequencing reaction according to the manufacturer's protocol using Pyro Gold Reagents and the PSQ96 MA System (Biotage). Sequence analysis and quantification of CpG-dinucleotide methylation was performed using Pyro Q-CpG software (Biotage). Cloning of PCR products was performed using the TOPO TA Cloning Kit with One Shot TOP10 chemically competent Escherichia coli and the pcDNA3.1/V5-His Vector (Invitrogen). Plasmids of at least nine positive clones were isolated using the QIAprep Spin Miniprep Kit (Qiagen) according to the manufacturer's protocol. Inserts were sequenced using the BigDye Terminator Cycle Sequencing Kit V1.1 (Applied Biosystems) and the T7 forward primer. The primers used for bisulphite genomic sequencing (amplification, cloning, sequencing) are given in the . Please note that all primers given in the  detect SMN1 and SMN2 due to identical promoter sequences.
###end p 48
###begin title 49
siRNA-mediated knockdown of MeCP2
###end title 49
###begin p 50
###xml 64 66 64 66 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DDN357C54">54</xref>
###xml 110 111 110 111 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 216 221 216 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MeCP2</italic>
siRNA-mediated knockdown was performed as described previously (54). Briefly, 1 day before transfection 1 x 105 SMA fibroblast cells were plated out in each well of a 6-well culture dish. Cells were transfected with MeCP2 siRNA (Qiagen, Hs_MeCP2_7, SI02664893, target sequence: ACG GAG CGG ATT GCA AAG CAA) or AllStars negative Control siRNA (Qiagen, 1027281) at a final concentration of 50 nM using DharmaFECT 1 siRNA Transfection Reagent (Dharmacon, Bonn, Germany). Transfection efficacy was controlled by transfection with siControl TOX transfection control (Dharmacon, D-001500-01-20). Cells were harvested after 48 h. RNA isolation and real-time PCR analyses were performed as described earlier.
###end p 50
###begin title 51
Chromatin immunoprecipitation
###end title 51
###begin p 52
###xml 151 152 151 152 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 469 470 469 470 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
ChIP experiments were carried out using the LowCell# ChIP Kit (Diagenode, Liege, Belgium) according to the manufacturer's instructions. Briefly, 3 x 105 fibroblast cells were used for each analysis. Cells were harvested by trypsinization. Proteins were cross-linked to DNA by adding formaldehyde to a final concentration of 1% for 8 min at room temperature to the trypsinized cells. The fixation reaction was stopped by adding glycine to a final concentration of 0.125 m and subsequent incubation for 10 min at room temperature. Chromatin was sheared using a Bioruptor (Diagenode), utilizing maximum power for 15 min with 30 s on/off cycles at 4degreesC. Five microgram of the MeCP2 antibody (Diagenode) per reaction was bound to the Protein A-coated paramagnetic beads which were included in the Kit. One hundered microlitre of sheared chromatin were added to the antibody-coated paramagnetic beads and incubated overnight at 4degreesC with rotation. Chromatin was immunoprecipitated and washed by using a Magnetic Rack (Diagenode). Thereafter DNA was purified from the antibody coated beads by using DNA purifying slurry and incubation of the samples in boiling water for 10 min. This step was followed by addition of proteinase K (Diagenode) and incubation at 55degreesC for 30 min in a thermomixer (1000 rpm). Subsequently the samples were incubated again in boiling water for 10 min to elute the DNA. DNA was analysed by real-time PCR on a 7500 Real-Time PCR System (Applied Biosystems), using Power SYBR Green PCR Master Mix (Applied Biosystems) and the primers listed in the . All PCRs were performed at least in triplicates.
###end p 52
###begin title 53
SUPPLEMENTARY MATERIAL
###end title 53
###begin p 54
.
###end p 54
###begin p 55
###xml 0 30 0 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Conflict of Interest statement</italic>
Conflict of Interest statement. None declared.
###end p 55
###begin title 56
FUNDING
###end title 56
###begin p 57
###xml 39 80 39 80 <grant-sponsor xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Initiative Forschung und Therapie f&#252;r SMA</grant-sponsor>
###xml 110 173 110 173 <grant-sponsor xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">K&#246;ln Fortune Program/Faculty of Medicine, University of Cologne</grant-sponsor>
###xml 191 228 191 228 <grant-sponsor xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Deutsche Forschungsgemeinschaft (DFG)</grant-sponsor>
###xml 267 292 267 292 <grant-sponsor xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Wilhelm Sander Foundation</grant-sponsor>
###xml 327 362 327 362 <grant-sponsor xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Families of Spinal Muscular Atrophy</grant-sponsor>
###xml 392 429 392 429 <grant-sponsor xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Center for Molecular Medicine Cologne</grant-sponsor>
This work was kindly supported by the 'Initiative Forschung und Therapie fur SMA' (to E.H. and to B.W.), the 'Koln Fortune Program/Faculty of Medicine, University of Cologne' (to E.H.), the 'Deutsche Forschungsgemeinschaft (DFG)' (to E.H., to I.B. and to B.W.), the 'Wilhelm Sander Foundation' (to E.H., I.Y.E. and I.B.), the 'Families of Spinal Muscular Atrophy' (to B.W. and E.H.) and the 'Center for Molecular Medicine Cologne' (to B.W. and E.H.). The 'Monash International Post graduate Research Scholarship (MIPRS)' and the 'Monash Graduate Scholarship (MGS)' (to S.L.). Funding to pay the Open Access charge was provided by the 'Initiative Forschung und Therapie fur SMA'.
###end p 57
###begin title 58
Supplementary Material
###end title 58
###begin title 59
[Supplementary Data]
###end title 59
###begin title 60
REFERENCES
###end title 60
###begin article-title 61
Spinal muscular atrophy: from gene to therapy
###end article-title 61
###begin article-title 62
An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA)
###end article-title 62
###begin article-title 63
Identification and characterization of a spinal muscular atrophy-determining gene
###end article-title 63
###begin article-title 64
A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy
###end article-title 64
###begin article-title 65
SMN oligomerization defect correlates with spinal muscular atrophy severity
###end article-title 65
###begin article-title 66
A non-sequence-specific requirement for SMN protein activity: the role of aminoglycosides in inducing elevated SMN protein levels
###end article-title 66
###begin article-title 67
###xml 103 107 <span type="species:ncbi:10090">mice</span>
SMNDelta7, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length SMN
###end article-title 67
###begin article-title 68
###xml 64 72 <span type="species:ncbi:9606">patients</span>
Identification of proximal spinal muscular atrophy carriers and patients by analysis of SMNT and SMNC gene copy number
###end article-title 68
###begin article-title 69
Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy
###end article-title 69
###begin article-title 70
###xml 16 24 <span type="species:ncbi:9606">patients</span>
Mildly affected patients with spinal muscular atrophy are partially protected by an increased SMN2 copy number
###end article-title 70
###begin article-title 71
Copies of the survival motor neuron gene in spinal muscular atrophy: the more, the better
###end article-title 71
###begin article-title 72
Animal models of spinal muscular atrophy
###end article-title 72
###begin article-title 73
###xml 62 69 <span type="species:ncbi:9606">patient</span>
Valproic acid increases SMN levels in spinal muscular atrophy patient cells
###end article-title 73
###begin article-title 74
Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy
###end article-title 74
###begin article-title 75
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
###xml 13 20 13 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ex vivo</italic>
In vitro and ex vivo evaluation of second-generation histone deacetylase inhibitors for the treatment of spinal muscular atrophy
###end article-title 75
###begin article-title 76
Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy
###end article-title 76
###begin article-title 77
Treatment of spinal muscular atrophy by sodium butyrate
###end article-title 77
###begin article-title 78
The benzamide M344, a novel histone deacetylase inhibitor, significantly increases SMN2 RNA/protein levels in spinal muscular atrophy cells
###end article-title 78
###begin article-title 79
The role of histone acetylation in SMN gene expression
###end article-title 79
###begin article-title 80
###xml 58 63 <span type="species:ncbi:10090">mouse</span>
Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy
###end article-title 80
###begin article-title 81
Establishing a standardized therapeutic testing protocol for spinal muscular atrophy
###end article-title 81
###begin article-title 82
Pilot trial of phenylbutyrate in spinal muscular atrophy
###end article-title 82
###begin article-title 83
###xml 72 80 <span type="species:ncbi:9606">patients</span>
Phenylbutyrate increases SMN gene expression in spinal muscular atrophy patients
###end article-title 83
###begin article-title 84
###xml 47 55 <span type="species:ncbi:9606">patients</span>
Valproate may improve strength and function in patients with type III/IV spinal muscle atrophy
###end article-title 84
###begin article-title 85
###xml 66 74 <span type="species:ncbi:9606">patients</span>
In vivo activation of SMN in spinal muscular atrophy carriers and patients treated with valproate
###end article-title 85
###begin article-title 86
Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription
###end article-title 86
###begin article-title 87
Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex
###end article-title 87
###begin article-title 88
###xml 29 34 <span type="species:ncbi:9606">human</span>
DNA methylation profiling of human chromosomes 6, 20 and 22
###end article-title 88
###begin article-title 89
DNA methylation landscapes: provocative insights from epigenomics
###end article-title 89
###begin article-title 90
###xml 25 30 <span type="species:ncbi:9606">human</span>
Promoter analysis of the human centromeric and telomeric survival motor neuron genes (SMNC and SMNT)
###end article-title 90
###begin article-title 91
Characterization of the survival motor neuron (SMN) promoter provides evidence for complex combinatorial regulation in undifferentiated and differentiated P19 cells
###end article-title 91
###begin article-title 92
Histone deacetylase inhibitors: possible implications for neurodegenerative disorders
###end article-title 92
###begin article-title 93
Survival motor neuron SMN1 and SMN2 gene promoters: identical sequences and differential expression in neurons and non-neuronal cells
###end article-title 93
###begin article-title 94
Demethylase activity is directed by histone acetylation
###end article-title 94
###begin article-title 95
Valproate induces replication-independent active DNA demethylation
###end article-title 95
###begin article-title 96
Valproate induces widespread epigenetic reprogramming which involves demethylation of specific genes
###end article-title 96
###begin article-title 97
Histone hyperacetylation induces demethylation of reelin and 67-kDa glutamic acid decarboxylase promoters
###end article-title 97
###begin article-title 98
Epigenetic programming by maternal behavior
###end article-title 98
###begin article-title 99
Genomic DNA methylation: the mark and its mediators
###end article-title 99
###begin article-title 100
###xml 93 98 <span type="species:ncbi:9606">human</span>
Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome
###end article-title 100
###begin article-title 101
###xml 51 56 <span type="species:ncbi:9606">human</span>
A genome-wide analysis of CpG dinucleotides in the human genome distinguishes two distinct classes of promoters
###end article-title 101
###begin article-title 102
SMN2 copy number predicts acute or chronic spinal muscular atrophy but does not account for intrafamilial variability in siblings
###end article-title 102
###begin article-title 103
###xml 2 7 <span type="species:ncbi:10090">mouse</span>
A mouse model for spinal muscular atrophy
###end article-title 103
###begin article-title 104
Molecular analysis of candidate genes on chromosome 5q13 in autosomal recessive spinal muscular atrophy: evidence of homozygous deletions of the SMN gene in unaffected individuals
###end article-title 104
###begin article-title 105
Plastin 3 is a protective modifier of autosomal recessive spinal muscular atrophy
###end article-title 105
###begin article-title 106
Histone deacetylase inhibitors
###end article-title 106
###begin article-title 107
Brahma links the SWI/SNF chromatin-remodeling complex with MeCP2-dependent transcriptional silencing
###end article-title 107
###begin article-title 108
International SMA consortium meeting. (26-28 June 1992, Bonn, Germany)
###end article-title 108
###begin article-title 109
###xml 78 86 <span type="species:ncbi:9606">patients</span>
Natural history in proximal spinal muscular atrophy. Clinical analysis of 445 patients and suggestions for a modification of existing classifications
###end article-title 109
###begin article-title 110
###xml 55 60 <span type="species:ncbi:9606">human</span>
A simple salting out procedure for extracting DNA from human nucleated cells
###end article-title 110
###begin article-title 111
A simple method for organotypic cultures of nervous tissue
###end article-title 111
###begin article-title 112
###xml 73 81 73 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 83 90 83 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ex vivo</italic>
###xml 95 102 95 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
Suberoylanilide hydroxamic acid (SAHA) has potent anti-glioma properties in vitro, ex vivo and in vivo
###end article-title 112
###begin article-title 113
De novo quantitative bisulfite sequencing using the pyrosequencing technology
###end article-title 113
###begin article-title 114
Nonsense-mediated messenger RNA decay of survival motor neuron 1 causes spinal muscular atrophy
###end article-title 114

